|
OKUYAMA Ryo
Department Ritsumeikan Asia Pacific University College of International Management Position Professor |
|
| Language | English |
| Publication Date | 2023/07 |
| Type | Research paper |
| Peer Review | Peer reviewed |
| Title | Advancements in Drug Repurposing: Examples in Psychiatric Medications. |
| Contribution Type | Single Work |
| Journal | International Journal of Molecular Sciences |
| Journal Type | Another Country |
| Publisher | MDPI |
| Volume, Issue, Page | 24(13),pp.11000 |
| Total page number | 10 |
| Authorship | Lead author,Corresponding author |
| Author and coauthor | Ryo Okuyama |
| Details | This study was aimed at uncovering recent trends in drug repurposing approaches and new technologies in psychiatric drug development. Psychiatric drugs that were approved by the FDA between 2002 and 2022 were listed, and the method of how the drug repurposing has been applied was analyzed. Drug repurposing has been increasingly applied to recently approved psychiatric drugs. All repurposed drugs approved before 2016 used either prodrugs or active metabolites, while all drugs approved in 2021 and beyond used fixed-dose combinations with sophisticated ideas. SmartCube®, which uses artificial intelligence to predict human drug efficacy from animal phenotypes, was developed and produced novel drugs that show clinical efficacy. Well-designed drug repurposing approaches and new technologies for predicting human drug efficacy based off of animal models would contribute to novel psychiatric drug development. |
| DOI | https://doi.org/10.3390/ijms241311000 |